Abstract
While the pharmacology of nonsteroidal antiinflammatory drugs (NSAIDS) has been extensively studied, the precise mechanism as to how NSAIDS function at immunological level is not fully understood. Alminoprofen is a newer NSAIDS with characteristic antiinflammatory function by inhibiting cylooxygenase and phospholipase A2 activity. Incubation of normal human mononuclear cells (MNC) with alminoprofen significantly inhibited IgG- and IgM-rheumatoid factor production in PWM-stimulated MNC. Alminoprofen also inhibited immunoglobulin production. On the other hand, alminoprofen did not inhibit IL-1 and TNF-a production by LPS-stimulated MNC.
The data suggest that the inhibition of rheumatoid factor production by activated MNC may contribute to the therapeutic role of alminoprofen in the management of immune dysfunction in rheumatoid arthritis patients although alminoprofen may differ from disease modifying antirheumatic drugs in immune regulation.
